Returns Breakdown
0.1
Return On Assets
0.0792
Return On Capital Employed
| Return On Tangible Assets | 0.15 | |
| Return On Capital Employed | 0.0792 | |
| Return On Assets | 0.1 | |
| Return On Equity | 0.15 |
Should you continue to rely on Hologic (USA Stocks:HOLX) management?
 | By Ellen Johnson | Macroaxis Story |
More than 99% of Hologic shares are held by institutional investors, such as mutual funds, pension funds, insurance companies, and large investment firms. These entities manage money on behalf of others, making their holdings a key indicator of the stock’s stability and confidence from big players. For a deeper look, check out our latest analysis of Hologic, including detailed ownership breakdowns and insights into who’s really backing the company.
Main Takeaways
Hologic (HOLX) continues to demonstrate steady momentum, with its open price at 73.91 and a typical day’s trading around 74.05, suggesting cautious optimism among investors. Given its EPS estimate for next year of 4.52 and a Wall Street target of 75, a breakout could be on the horizon if buying volume sustains, especially as the stock’s market risk-adjusted performance remains positive at 0.2228.Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Raphi Shpitalnik
Hologic (HOLX) has been demonstrating steady upward movement, with its current market valuation hovering around $74, close to its 50-day moving average of approximately $68.28. Despite facing a recent loss of around $0.20 per share, the company’s overall outlook remains positive, supported by an analyst consensus rating of Buy and a target price near $75. The stock’s beta of 0.627 suggests it’s less volatile than the broader market, and with a relatively low short interest of 3.5 million shares, there’s potential for a breakout if buying momentum continues. While some downside risk exists around $72.77, the stock’s recent performance and analyst expectations point toward further gains ahead. Currently, Hologic’s Payables Turnover remains steady compared to last year, indicating stable supplier relationships. Looking ahead, the company’s Research and Development to Revenue ratio is expected to increase to 0.09 by 2025, signaling more investment in innovation. Meanwhile, the Price-to-Sales ratio is projected to decrease to around 2.16, which could suggest the stock is becoming more attractively valued. This brief overview aims to analyze Hologic as a potential investment for December. We’ll explore why recent price movements hint at a possible rebound next month, considering factors like valuation shifts and market sentiment. Overall, Hologic appears poised for some upward momentum, making it worth watching as the year wraps up.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Hologic. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Predictive Modules for Hologic
How important is Hologic's Liquidity
Hologic financial leverage refers to using borrowed capital as a funding source to finance Hologic ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Hologic financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Hologic's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Hologic's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Hologic's total debt and its cash.
Hologic Gross Profit
Hologic Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Hologic previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Hologic Gross Profit growth over the last 10 years. Please check Hologic's gross profit and other fundamental indicators for more details.
An Additional Perspective On Hologic
Hologic has relatively low volatility with skewness of 1.39 and kurtosis of 6.79. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Hologic's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Hologic's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.
A penny saved is a penny earned, and for Hologic (HOLX), steady gains suggest the company is on a cautious upward trajectory. With a current share price around $74.05 and a 52-week high of $84.39, the stock shows resilience within its industry of Medical Instruments & Supplies. Its solid cash flow from operations of $1.29 billion and a market cap of $16.45 billion highlight its financial stability, despite a modest operating margin of 0.25%. The stock's valuation metrics, including a PE ratio of approximately 30.67 and a Price to Sales of 4.07X, indicate it’s fairly valued relative to its growth prospects, with Wall Street targeting around $75. While the current downside deviation and semi variance suggest some risk, the high institutional ownership of 99.15% signals strong confidence from big players, hinting that a breakout could be on the horizon if the company maintains its momentum..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Hologic. Please refer to our Terms of Use for any information regarding our disclosure principles.